Status:
NOT_YET_RECRUITING
Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Polycythemia Vera
Essential Thrombocythaemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Philadelphia-negative myeloproliferative neoplasms (MPNs) occur sporadically and are due to somatic mutations in the JAK2 (Janus kinase 2), CALR (calreticulin) and MPL (thrombopoietin receptor) genes....
Eligibility Criteria
Inclusion
- \*Patients \>18 years
- Diagnosis of MPN (Essential Thrombocythemia, Polycythemia Vera, Myelofibrosis) confirmed according to ICC 2022 criteria
- Familiarity for myeloid neoplasia: at least one first or second degree relative affected by myeloid neoplasia (probands) OR presence of matching criteria with a proband (controls). Each center will be able to contribute with its own available patients/relatives, providing the clinical-laboratory data required by the study.
- Signing of informed consent according to ICH/EU/GCP and local national laws (if applicable)
Exclusion
- Patients \<18 years Patients with other hematological diagnoses; • Lack of informed consen
Key Trial Info
Start Date :
May 21 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2028
Estimated Enrollment :
496 Patients enrolled
Trial Details
Trial ID
NCT06923670
Start Date
May 21 2025
End Date
May 1 2028
Last Update
May 15 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.